Pathophysiology of metabolic syndrome-The role of central obesity
Odoh G |
Uwakwe JN |
Edah JO |
Ojobi JE |
Chuhwak EK |
Article Number: irjmbs.19.002 | Pages: 8-12 | Vol.4 (1), January 2019 | DOI: https://doi.org/10.15739/irjmbs.19.002
Received: November 23, 2018 Accepted: January 23, 2019 Published: January 28, 2019
Abstract
The term Metabolic Syndrome (MetS) refers to the clustering of a number of cardiovascular risk factors: obesity (usually central), hypertension, dyslipidaemia, glucose intolerance, prothrombotic state and inflammation. MetS is a predictor of type 2 diabetes mellitus and cardiovascular disease. Jean Vague in the 1940s and early 1950s related the presence of male type (android form) of adiposity to the development of diabetes mellitus and cardiovascular diseases which are all important factors of the MetS. MetS is defined based on a variety of criteria, such as the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III), World Health Organization (WHO) and International Diabetes Federation (IDF) .Central obesity is an important component of MetS in these definitions. This is largely due to the key role played by the adipocyte in the development of the syndrome. The contents of this article were drawn from an extensive online search of literature covering the subject matter, and aims to review the pathophysiological role of central obesity in the development of the components of the metabolic syndrome.
Keywords: Obesity, diabetes mellitus, cholesterol, cardiovascular risk
How to Cite this Article
Author(s) retain the copyright of this article. Author(s) agree that this article remain permanently open access under the terms of the Creative Commons Attribution License 4.0 International License.